Karyopharm Therapeutics Inc (NASDAQ: KPTI) kicked off on Friday, up 6.24% from the previous trading day, before settling in for the closing price of $8.17. Over the past 52 weeks, KPTI has traded in a range of $3.51-$11.40.
Annual sales at Healthcare sector company grew by 27.91% over the past five years. While this was happening, its average annual earnings per share was recorded 12.70%. With a float of $17.08 million, this company’s outstanding shares have now reached $18.31 million.
Karyopharm Therapeutics Inc (KPTI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 6.73%, while institutional ownership is 37.77%. The most recent insider transaction that took place on Oct 01 ’25, was worth 2,279. In this transaction Chief Accounting Officer of this company sold 362 shares at a rate of $6.30, taking the stock ownership to the 10,046 shares. Before that another transaction happened on Sep 15 ’25, when Company’s President and CEO sold 1,257 for $6.43, making the entire transaction worth $8,083. This insider now owns 84,046 shares in total.
Karyopharm Therapeutics Inc (KPTI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -3.6 earnings per share (EPS), higher than consensus estimate (set at -4.03) by 0.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 50.91% during the next five years compared to 27.91% growth over the previous five years of trading.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Take a look at Karyopharm Therapeutics Inc’s (KPTI) current performance indicators. Last quarter, stock had a quick ratio of 0.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -14.58, a number that is poised to hit -2.08 in the next quarter and is forecasted to reach -5.92 in one year’s time.
